EU PV for Retapamulin-Prescribing

Status Completed

Clinical Trial Summary

Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more months of age. This study is designed to examine retapamulin use in the pediatric population less than nine months of age. We will conduct a five-year assessment of prescriptions for retapamulin using the General Practice Research Database. For each year of reporting, the observed frequencies of prescriptions of retapamulin, with or without same-day co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year reporting period will include five years of distinct, non-overlapping, non-cumulative prescription use of first exposure to retapamulin, with or without same-day co-prescription of topical mupirocin or fusidic acid.

Clinical Trial Description

n/a

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Impetigo

Clinical Trial Details

NCT number	NCT01153828
Study type	Observational
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	N/A
Start date	November 2008
Completion date	August 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00884728` - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory	N/A
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A
Active, not recruiting	`NCT05226260` - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care	N/A
Terminated	`NCT00986856` - Fucidin® Cream in the Treatment of Impetigo	Phase 4
Completed	`NCT01397461` - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo	Phase 3
Recruiting	`NCT02090764` - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo	Phase 3
Completed	`NCT02775617` - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease	Phase 4
Not yet recruiting	`NCT01611909` - Citriodiol® and Impetigo	Phase 2/Phase 3
Completed	`NCT03177993` - Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji	N/A
Completed	`NCT03429595` - Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo	Phase 2
Completed	`NCT04287777` - Safety and Efficacy of Mupirocin Gel in Children With Impetigo	Phase 3
Completed	`NCT00626795` - Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)	Phase 2
Completed	`NCT00758862` - The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo	Phase 2
Recruiting	`NCT01943136` - The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial	Phase 1
Completed	`NCT01670032` - Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo	Phase 2/Phase 3
Completed	`NCT01171326` - Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients	Phase 2
Completed	`NCT01367314` - Safety and Efficacy of Topical NVC-422 Gel in Impetigo	Phase 2
Completed	`NCT01126268` - Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection	Phase 4
Completed	`NCT00852540` - Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA	Phase 3
Completed	`NCT00133848` - Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment	Phase 3